After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
Avidity Biosciences Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Avidity Biosciences Inc is $3.85B. A total of 1.58 million shares were traded on the day, compared to an average of 1.34M shares.
In the most recent transaction, Hughes Steven George sold 9,578 shares of RNA for 31.06 per share on Mar 20 ’25. After the transaction, the Chief Medical Officer now owns 72,850 company shares. In a previous transaction on Mar 20 ’25, Boyce Sarah sold 31,540 shares at 31.06 per share. RNA shares that President and CEO owns now total 305,871.
Among the insiders who sold shares, Flanagan W. Michael disposed of 11,780 shares on Mar 20 ’25 at a per-share price of $31.06. This resulted in the Chief Scientific Officer holding 80,195 shares of RNA after the transaction. In another insider transaction, MacLean Michael F sold 7,935 shares at $31.06 per share on Mar 20 ’25. Company shares held by the Chief Financial Officer now total 96,720.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, RNA has a high of $56.00 and a low of $21.56.
As of this writing, RNA has an earnings estimate of -$0.88 per share for the current quarter. EPS was calculated based on a consensus of 11.0 estimates, with a high estimate of -$0.55 per share and a lower estimate of -$1.07.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. RNA’s latest balance sheet shows that the firm has $405.54M in Cash & Short Term Investments as of fiscal 2021. There were $11.73M in debt and $29.66M in liabilities at the time. Its Book Value Per Share was $11.89, while its Total Shareholder’s Equity was $381.43M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RNA is Buy with a score of 4.86.
